Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.
A Northwestern Medicine study published in Nature Communications has revealed how HIV can protect infected cells by altering ...
In a groundbreaking discovery, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human ...
A trial was about to launch for a vaccine that would ward off the HIV virus. It would be an incredible breakthrough. Then it ...
In 2022, there were up to 1.2 million people with HIV (PWH) and 37,981 new cases of HIV in the United States alone. 1 While impressive advances have been made in HIV treatment and prevention, there ...
Human immunodeficiency virus (HIV) infections are lifelong, potentially life-threatening infections that weaken an individual’s immune system, rendering them susceptible to severe secondary infections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback